The European Medicines Agency is this week due to decide whether to recommend EU-wide marketing approval for 13 products, including AstraZeneca/Sanofi’s long-acting monoclonal antibody, nirsevimab, for immunizing infants to prevent lower respiratory tract infection caused by the respiratory syncytial virus (RSV).
AstraZeneca/Sanofi’s RSV Shot Among 13 Hopefuls Awaiting EU Verdict
Its crunch time for sponsors of more than a dozen products as the EMA meets to adopt opinions on several marketing authorization applications.
